Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03686488 · ClinicalTrials.gov registry record · Phase 2
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03686488 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 23 participants.
The verdict
NCT03686488, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the combination of TAS 102 and Ramucirumab is safe and effective in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Interventions
- DRUG TAS 102
- DRUG Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2024-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03686488
The ClinicalTrials.gov registry entry for NCT03686488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAS 102 is the first listed.
NCT03686488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03686488 about?
NCT03686488 is a clinical study titled "TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma". The purpose of this study is to find out if the combination of TAS 102 and Ramucirumab is safe and effective in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
What is the current status of trial NCT03686488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2018-12-20. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT03686488?
The interventions under investigation include: TAS 102 (DRUG), Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA] (DRUG).
Who is sponsoring clinical trial NCT03686488?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.